STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER
Elshwadfy, S., Hesham, M., Mohammed, M., Fawzy, A. (2023). STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER. EKB Journal Management System, 29(1.1), 159-166. doi: 10.21608/zumj.2020.23937.1740
Suzan Atia Elshwadfy; Mervat Abdallah Hesham; Mervat Atfy Mohammed; Amal Fawzy. "STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER". EKB Journal Management System, 29, 1.1, 2023, 159-166. doi: 10.21608/zumj.2020.23937.1740
Elshwadfy, S., Hesham, M., Mohammed, M., Fawzy, A. (2023). 'STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER', EKB Journal Management System, 29(1.1), pp. 159-166. doi: 10.21608/zumj.2020.23937.1740
Elshwadfy, S., Hesham, M., Mohammed, M., Fawzy, A. STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER. EKB Journal Management System, 2023; 29(1.1): 159-166. doi: 10.21608/zumj.2020.23937.1740

STUDY OF CLINICAL AND PROTHROMBOTIC GENE MUTATION AS PREDICTORS OF THROMBOEMBOLISM IN PEDIATRIC CANCER

Zagazig University Medical Journal
Article 23, Volume 29, Issue 1.1, January 2023, Page 159-166  XML PDF (355.92 K)
Document Type: Original Article
DOI: 10.21608/zumj.2020.23937.1740
View on SCiNiTO View on SCiNiTO
Authors
Suzan Atia Elshwadfy email 1; Mervat Abdallah Heshamorcid 2; Mervat Atfy Mohammed3; Amal Fawzy4
1Pediatric department,zagazig university
2pediatric department, faculity of medicine, Zagazig university
3Pediatrics Department, Faculty of Medicine, Zagazig University.
4Clinical Biochemistry Department, Faculty of Medicine, Zagazig University.
Abstract
Background:Thromboembolism is a well-recognized complication in children with cancer and associated with chronic morbidity, delay of treatment, adverse events associated with anticoagulation and rarely mortality ,so we aimed to study the relation between susceptibility to prothrombotic defects and pediatric cancers.Methods: this case control study included 50 patients aged from 1-14 years categorized into two groups: 25 children with newly diagnosed cancer as case group and 25 completely healthy, age and sex matched children as control group.All subjects were tested for prothrombin gene mutation by Polymerase chain reaction and evaluated for other clinical and laboratory risk factors for TE in children with cancer including age ,sex,blood group,cancer type ,chemotherapy received,central venous catheter insertion,past history of TE,family history of TE,clinical presentation, level of serum protein C,serum protein S, D-Dimer،(INR) then all cases were followed for 3 months after starting chemotherapy.Results:Out of 25 pediatric patients with cancer, 28% had heterozygous prothrombin gene mutation ,while 16% of control group had the same mutation.Also 4% of studied patients developed TE.There was non-significant difference between studied groups regarding prothrombin gene mutation and there was significant difference between them according to PS,PC,D-dimer, prothrombin time and platelets counts.There were non-significant relation between prothrombin gene mutation and either gender,age,family,past history of TE or cancer type and development of thromboembolism. Conclusion:There was a relationship between the age,presence of family or past history of TE,non O blood group,exposure to steroids and asparginase,presence of CVC,prothrombin gene mutation as strong risk factors for TE and pediatric cancer.Keywords: Thromboembolism,Prothrombin gene mutation,Pediatric cancer.
Keywords
Keywords: Thromboembolism; Prothrombin gene mutation; Pediatric cancer
Statistics
Article View: 219
PDF Download: 93